TY  - JOUR
AU  - Iacoboni, Gloria
AU  - Villacampa, Guillermo
AU  - Martinez-Cibrian, Nuria
AU  - Bailén, Rebeca
AU  - Lopez Corral, Lucia
AU  - Sanchez, Jose M
AU  - Guerreiro, Manuel
AU  - Caballero, Ana Carolina
AU  - Mussetti, Alberto
AU  - Sancho, Juan-Manuel
AU  - Hernani, Rafael
AU  - Abrisqueta, Pau
AU  - Solano, Carlos
AU  - Sureda, Anna
AU  - Briones, Javier
AU  - Martin Garcia-Sancho, Alejandro
AU  - Kwon, Mi
AU  - Reguera-Ortega, Juan Luis
AU  - Barba, Pere
AU  - GETH, GELTAMO Spanish Groups
PY  - 2021
DO  - 10.1002/cam4.3881
UR  - http://hdl.handle.net/10668/17730
T2  - Cancer medicine
AB  - Tisagenlecleucel (tisa-cel) is a second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The approval was based on the results of phase II JULIET...
LA  - en
KW  - clinical cancer research
KW  - clinical observations
KW  - hematological cancer
KW  - non-Hodgkin's lymphoma
KW  - Aged
KW  - Cytokines
KW  - Female
KW  - Humans
KW  - Leukapheresis
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Progression-Free Survival
KW  - Receptors, Antigen, T-Cell
KW  - Receptors, Chimeric Antigen
KW  - Retrospective Studies
KW  - Standard of Care
TI  - Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
TY  - research article
VL  - 10
ER  -